Whereas some germline TREX1 variants may have pathogenic effects in autoimmune disorders, some of the same functional variants may provide a therapeutic vulnerability in cancer treatment by dampening or abrogating TREX1 activity and increasing antitumor immune response. The gene discussed is TREX1; the disease is autoimmune disease.